SCHEMBL7004085

SCHEMBL7004085

CC(C)(C)OC(=O)N1CC(O)c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.50
BCHE P06276 1/20 0.46
NOTUM Q6P988 1/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
GPR119 Q8TDV5 1/20 0.40
NAMPT P43490 1/20 0.39
SCN9A Q15858 2/20 0.39
SCN5A Q14524 1/20 0.39
RORC P51449 1/20 0.38
UCHL1 P09936 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
USP30 Q70CQ3 1/20 0.37
MAPK1 P28482 1/20 0.36
KDM4E B2RXH2 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29457639 0.87 KDM1A (0.55) KDM1ABCHENOTUMHDAC1HDAC6
SCHEMBL29457605 0.87 KDM1A (0.55) KDM1ABCHENOTUMHDAC1HDAC6
SCHEMBL2174623 0.87 KDM1A (0.55) KDM1ABCHENOTUMHDAC1HDAC6
SCHEMBL8016162 0.85 NOTUM (0.63) KDM1ABCHENOTUMHDAC1HDAC6
SCHEMBL14222127 0.84 KDM1A (0.46) KDM1ABCHENOTUMHDAC1HDAC6
SCHEMBL30346095 0.84 KDM1A (0.52) KDM1ABCHENOTUMHDAC1HDAC6
SCHEMBL3707225 0.84 KDM1A (0.52) KDM1ABCHENOTUMHDAC1HDAC6
SCHEMBL3406623 0.83 NOTUM (0.46) KDM1ABCHENOTUMHDAC1HDAC6
SCHEMBL8562821 0.83 NOTUM (0.46) KDM1ABCHENOTUMHDAC1HDAC6
SCHEMBL5560266 0.82 KDM1A (0.44) KDM1ABCHENOTUMHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030105118-A1 Tricyclic quinazolinediones SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-06-05 US disclosed
EP-1288216-A1 TRICYCLIC QUINAZOLINEDIONES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105118-A1 Tricyclic quinazolinediones PARP1, PARP11, PARP2 KDM1A 739/4885BCHE 3557/4885NOTUM 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.